Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

A Mounjaro user has revealed what happened when they accidentally overdosed using the controversial 'golden dose'. ICYMI, ...

Researchers observed inequities in receipt of first-line preferred therapies among a cohort of patients with chronic ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

TD Cowen has lowered Eli Lilly’s price target from $1,050 to $960, but maintained a Buy rating, citing solid long-term ...

The Gabelli Growth Fund (GABGX) returned (8.5)% during Q1 of 2025 vs. (10.0)% return for the Russell 1000 Growth Index. Click ...

This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Weber, a New York Times bestselling author and ordained Lutheran pastor, will speak in Staples Auditorium on the campus of ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

This was the stock's fifth consecutive day of gains.